Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

eatment  
  • There was no statistical difference in PASP between the LEVADEX and placebo groups over two hours
  • No significant electrocardiogram (ECG) changes were observed
  • Adverse events were more frequent in the IV DHE group than in the LEVADEX or placebo groups

    • The three additional LEVADEX related presentations are:
    Utility of LEVADEX (MAP0004) in Situations Where Early Intervention Paradigm Is Impractical
    Session Info: Platform Session: April 12, 2011, 3:00-4:30 p.m. HAST
    Presentation Info: April 12, 2011 at 3:45 p.m. HAST
    Presentation #: 004

    This presentation has been selected by the Scientific Program Subcommittee to be in the top five percent of the American Academy of Neurology presentations and, as such, LEVADEX will be highlighted by the Subcommittee during the Scientific Program Highlights Plenary Session on Friday, April 15, 5:15 – 6:15 p.m.

    The Major Metabolite of Dihydroergotamine (DHE) after Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacologic Activity
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 272

    Migraine Recurrence Rates: Case for Standardization of the Definition
    Session Info: Poster Session 5: April 13, 2011, 2:00-6:30 p.m. HAST
    Poster #: 285

    About LEVADEX® LEVADEX is an investigational acute drug for migraine that has completed Phase 3 clinical development.  In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler.  LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo fo
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/19/2013)... Today MedeAnalytics, a leading provider of ... its Employer Group and Individual Business Analytics ... their employer groups an intuitive and insightful view ... drug claims, network utilization, and overall financial impact. ... "Employer Group and Individual Business Analytics ...
    (Date:6/19/2013)... 2013  It may seem like an odd pairing: an ... But these were two of the most talked about topics ... Meeting & Expo that just convened in San ... by some of the top internal medicine experts in the ... research that can not only save lives, but help people ...
    (Date:6/18/2013)... -- Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ), a ... commercialization of novel bile acid therapeutics to treat chronic ... public offering of 1,730,000 shares of its common stock ... In addition, Intercept has granted the underwriters a 30-day ... of common stock. All of the shares ...
    Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
    ... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
    ... Covance Inc. (NYSE: CVD ) today announced that ... Tuesday, May 10, 2011 at 3:00 p.m. ET.  Investors may ... .  In order to register and download any necessary software, ... headquarters in Princeton, New Jersey, is one of the world,s ...
    Cached Medicine Technology:Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7Covance to Present at Baird's 2011 Growth Stock Conference 2
    (Date:6/19/2013)... Albany, NY (PRWEB) June 19, 2013 ... Global Industry Size, Market Share, Trends, Analysis and Forecast, ... worth USD 6.2 billion in the year 2011 and ... growing at a CAGR of 9.7% from 2011 to ... overall endoscopes market, contributing about USD 2,201 million for ...
    (Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
    (Date:6/19/2013)... MAYWOOD, Il. A Loyola University Chicago Niehoff School ... grant to study whether Vitamin D can improve mood ... study also will examine whether vitamin D supplementation can ... their diabetes. The grant is from the National Institute ... , Principal investigator Sue M. Penckofer, PhD, RN and ...
    (Date:6/19/2013)... AquaPrint Solutions in Thomson, IL is proud to present ... Harley Davidson motorcycle gas tank. A couple of weeks ago, ... of taking a split tank motorcycle that had been roughed ... a work of art. , In October of 2012, ... that had been dipped in a water transfer printer with ...
    (Date:6/19/2013)... 2013 Fit Body Boot Camp in ... a charity boot camp in order to support Orlando resident, ... boot camp franchise hosted the Brent Can Breathe fundraiser ... 75 boot camp participants and collected over $700. , Officially ... the second fundraiser held for Orlando local Brent Snyder, 24, ...
    Breaking Medicine News(10 mins):Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2
    ... Minority Quality Forum Launches First U.S. HIV/AIDS Atlas , ... today launched a groundbreaking HIV/AIDS Atlas ( http://www.MapHIV.org ... epidemic in communities across the United States. The Atlas ... location for the first time, painting a comprehensive picture of ...
    ... Perfect Time for Fitness! , , LOS ANGELES, June 22 ... in the park or along the beach. Now a brand new ... fitness equipment on wheels, but with a unique design to allow ... a new concept of fitness, will be introduced to California starting ...
    ... , DentaBurst(TM) delivers an on-the-go oral care solution to ... NEW YORK, June 22 Crown Consumer Brands today ... the original proven technology will remain intact, an improved, ... will accompany this highly anticipated re-launch. , ...
    ... MUSCLEPHARM(R) LLC, the rising star of the Sports Nutrition ... through each of Vitamin Shoppe,s 400+ locations nationwide. , ... launch of our entire line of products," MUSCLEPHARM president ... athletes in nearly every neighborhood across the nation! Vitamin ...
    ... Transcend Medical, Inc., an ophthalmic device company dedicated ... announced today that it has closed a $35 million ... of its Transcend CyPass(TM) System, a novel proprietary system ... Lead investor HLM Venture Partners, along with other new ...
    ... Magnetic Resonance Center of the University Children,s Hospital ... in MR-guided, non-invasive neurosurgery. Ten patients have been ... ultrasound. This fully non-invasive procedure opens new horizons ... brain disorders. In the context of a ...
    Cached Medicine News:Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 2Health News:MapHIV.org Shows 18% of Georgia's Counties are Seriously Impacted by HIV 3Health News:Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 2Health News:Crown Consumer Brands Re-Launches DentaBurst(TM) Freshening Teeth Cleaners 2Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2Health News:Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment 2Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 2Health News:Successful neurosurgery with transcranial MR-guided high-intensity focused ultrasound 3
    ... Sensor Intravascular Mikro-Tip Pressure Catheters; Millar ... dual pressure sensor catheters for simultaneous ... are suitable for measuring pressure gradients ... across a vascular stenosis. The catheters ...
    ... Dual Pressure Sensor Intravascular Mikro-Tip ... a line of dual pressure sensor ... measurements. These catheters are suitable for ... between chambers, or across a vascular ...
    ... TITAN, a high-resolution modular ultrasound solution. ... state of the art high-resolution imaging ... care. The TITAN system's modular design ... and mobile usage. , Point-of-care connectivity. ...
    ... The XTD Thrombectomy catheter is a ... remove thrombus from occluded hemodialysis access grafts. ... and consists of a rotatable, spiral shaft ... as a flexible, distal curved tip. In ...
    Medicine Products: